Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 3/20 | 0.48 |
| ▸ | TDO2 | P48775 | 15/20 | 0.47 |
| ▸ | IDO1 | P14902 | 13/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22732889 | 0.88 | TOP2A (0.59) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL23422787 | 0.79 | TOP2A (0.54) | TOP2ASMN1; SMN2DHODHTDO2IDO1 | |
| SCHEMBL25132524 | 0.79 | TOP2A (0.43) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25129541 | 0.79 | TTR (0.45) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25129809 | 0.76 | TOP2A (0.43) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25132883 | 0.76 | TTR (0.45) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL22478608 | 0.75 | TOP2A (0.42) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL24483711 | 0.74 | TOP2A (0.44) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL25603214 | 0.73 | ALDH1A1 (0.43) | TOP2ASMN1; SMN2ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL23422779 | 0.72 | TOP2A (0.54) | TOP2ASMN1; SMN2ALDH1A1DHODHTDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-11717511-B2 | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | HUEN CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-11717511-B2 | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | HUEN CO., LTD. (KR) | 2023-08-08 | — | — | US | disclosed |
| US-20210155596-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR PREVENTING OR TREATING SOLID CANCER OR BLOOD CANCER | HUEN CO., LTD. (KR) | 2021-05-27 | — | — | US | disclosed |
| WO-2020246807-A2 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, CONTAINING NAPHTHOQUINONE COMPOUND | 주식회사 엘마이토테라퓨틱스 | 2020-12-10 | — | — | WO | disclosed |
| WO-2020242277-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES COMPRISING NAPHTHOQUINONE DERIVATIVE | 주식회사 엘마이토테라퓨틱스 | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717511-B2 | Pharmaceutical composition comprising derivative compound of 1,2-naphthoquinone for preventing or treating solid cancer or blood cancer | MCL1, SNX1, ABL1 | TOP2A 395/4885SMN1; SMN2 699/4885ALDH1A1 458/4885 |
| US-20210155596-A1 | PHARMACEUTICAL COMPOSITION COMPRISING DERIVATIVE COMPOUND OF 1,2-NAPHTHOQUINONE FOR PREVENTING OR TREATING SOLID CANCER OR BLOOD CANCER | MCL1, SNX1, ABL1 | TOP2A 395/4885SMN1; SMN2 699/4885ALDH1A1 458/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | TOP2A 367/4885SMN1; SMN2 3061/4885ALDH1A1 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.